tetano
Editor, Senior Moderator
Euro Surveill. 2017 Oct;22(41). doi: 10.2807/1560-7917.ES.2017.22.41.17-00645.
[h=1]Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.[/h] Rondy M[SUP]1[/SUP], Gherasim A[SUP]2,[/SUP][SUP]3[/SUP], Casado I[SUP]4,[/SUP][SUP]2[/SUP], Launay O[SUP]5,[/SUP][SUP]6[/SUP], Rizzo C[SUP]7[/SUP], Pitigoi D[SUP]8[/SUP], Mickiene A[SUP]9[/SUP], Marbus SD[SUP]10[/SUP], Machado A[SUP]11[/SUP], Syrj?nen RK[SUP]12[/SUP], Pem-Novose I[SUP]13[/SUP], Horv?th JK[SUP]14[/SUP], Larrauri A[SUP]2,[/SUP][SUP]3[/SUP], Castilla J[SUP]4,[/SUP][SUP]2[/SUP], Vanhems P[SUP]15,[/SUP][SUP]16,[/SUP][SUP]6[/SUP], Alfonsi V[SUP]7[/SUP], Ivanciuc AE[SUP]17[/SUP], Kuliese M[SUP]9[/SUP], van Gageldonk-Lafeber R[SUP]10[/SUP], Gomez V[SUP]11[/SUP], Ikonen N[SUP]18[/SUP], Lovric Z[SUP]13[/SUP], Ferenczi A[SUP]14[/SUP], I-Move Hospital Working Group[SUP]19[/SUP], Moren A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
[h=4]KEYWORDS:[/h] A(H3N2); Influenza; cases control; elderly; hospitalisation; vaccine effectiveness
PMID: 29043961 DOI: 10.2807/1560-7917.ES.2017.22.41.17-00645
[h=1]Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.[/h] Rondy M[SUP]1[/SUP], Gherasim A[SUP]2,[/SUP][SUP]3[/SUP], Casado I[SUP]4,[/SUP][SUP]2[/SUP], Launay O[SUP]5,[/SUP][SUP]6[/SUP], Rizzo C[SUP]7[/SUP], Pitigoi D[SUP]8[/SUP], Mickiene A[SUP]9[/SUP], Marbus SD[SUP]10[/SUP], Machado A[SUP]11[/SUP], Syrj?nen RK[SUP]12[/SUP], Pem-Novose I[SUP]13[/SUP], Horv?th JK[SUP]14[/SUP], Larrauri A[SUP]2,[/SUP][SUP]3[/SUP], Castilla J[SUP]4,[/SUP][SUP]2[/SUP], Vanhems P[SUP]15,[/SUP][SUP]16,[/SUP][SUP]6[/SUP], Alfonsi V[SUP]7[/SUP], Ivanciuc AE[SUP]17[/SUP], Kuliese M[SUP]9[/SUP], van Gageldonk-Lafeber R[SUP]10[/SUP], Gomez V[SUP]11[/SUP], Ikonen N[SUP]18[/SUP], Lovric Z[SUP]13[/SUP], Ferenczi A[SUP]14[/SUP], I-Move Hospital Working Group[SUP]19[/SUP], Moren A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
[h=4]KEYWORDS:[/h] A(H3N2); Influenza; cases control; elderly; hospitalisation; vaccine effectiveness
PMID: 29043961 DOI: 10.2807/1560-7917.ES.2017.22.41.17-00645